Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
VX-702
Cat No.
CEI-0145
Description
VX-702 can inhibit p38 mitogen-activated protein kinase with IC50 of 4-20 nM.
CAS No.
745833-23-2
Molecular Weight
404.3
Purity
>99%
Storage
2 years at -20 centigrade
Targets
p38 MAPK
Molecular Formula
C19H12F4N4O2
Chemical Name
1-(5-carbamoyl-6-(2,4-difluorophenyl)pyridin-2-yl)-1-(2,6-difluorophenyl)urea
Solubility
DSMO 81 mg/mL Water
In vitro
As a second generation p38 MAPK inhibitor, VX-702 can inhibit p38 mitogen-activated protein kinase with IC50 of 4-20 nM.Pre-treatment of platelets with 1 microM VX-702 completely inhibited activation of p38 MAPK by thrombin, SFLLRN, AYPGKF, U46619, and collagen.There was no effect of VX-702 on platelet aggregation induced by any of the agonists in the presence or absence of aspirin, heparin or apyrase. VX-702 has no effect on collagen-mediated platelet aggregation. VX-702 do not significantly affect platelet function and would not be expected to contribute to an elevated risk of bleeding side-effects in treated patients. VX-702 shows potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases.
In vivo
VX-702 is not a substrate for renal organic anion and organic cation transport systems. In rat kidney (IPRK) model, VX-702 excretion was linear over the range of 100ng/mL to 600 ng/mL.
Download
Download Datasheet